Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K (1976). “A new antifungal antibiotic, trichostatin”. J. Antibiot.29 (1): 1-6. doi:10.7164/antibiotics.29.1. PMID931784.
Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005). “Clinical development of histone deacetylase inhibitors as anticancer agents”. Annu Rev Pharmacol Toxicol45: 495–528. doi:10.1146/annurev.pharmtox.45.120403.095825. PMID15822187.
Shankar S, Srivastava RK (2008). “Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis”. Adv Exp Med Biol. Advances in Experimental Medicine and Biology 615: 261–98. doi:10.1007/978-1-4020-6554-5_13. ISBN978-1-4020-6553-8. PMID18437899.
Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K (1976). “A new antifungal antibiotic, trichostatin”. J. Antibiot.29 (1): 1-6. doi:10.7164/antibiotics.29.1. PMID931784.
Vanhaecke T, Papeleu P, Elaut G, Rogiers V (2004). “Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view”. Curr Med Chem11 (12): 1629–43. PMID15180568.
Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005). “Clinical development of histone deacetylase inhibitors as anticancer agents”. Annu Rev Pharmacol Toxicol45: 495–528. doi:10.1146/annurev.pharmtox.45.120403.095825. PMID15822187.
Shankar S, Srivastava RK (2008). “Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis”. Adv Exp Med Biol. Advances in Experimental Medicine and Biology 615: 261–98. doi:10.1007/978-1-4020-6554-5_13. ISBN978-1-4020-6553-8. PMID18437899.